

DERMA PEARLS : THERAPEUTICS- 9

Molluscum Contagiosum : Treatment Options & Therapeutic Gaps

- ❑ FDA recently approved topical cantharidin novel drug-in-device combination which is administered by health care providers.
- ❑ Y canth(cantharidin) It is a standardized formulation of pharmaceutical-grade cantharidin 0.7% in a single-use applicator topically applied every 3 weeks as needed, with targeted dosing and delivery in adults and Pediatric patients of 2 years & older.
- ❑ The mechanism of action of cantharidin is the vesicant effect, which includes cell lysis contained in the epidermis
- ❑ Reported adverse events : blistering (10–100%), discomfort or pain (7–86%), and dyschromia (2–54%).
- ❖ **Berdazimer gel** a first-in-class nitric oxide (NO)-releasing topical treatment. This **self-treatment approach** incorporates the ability to activate nitric oxide upon application, which has been shown to effectively reduce MC lesions
- ❖ Berdazimer gel 10.3% (Zelsuvmi) includes adults and children ages 1 yr & Older.



IADVL – AP
TEAM GUNTUR

Further Reading:

J Clin Aesthet Dermatol 2023;16(8 Suppl 1):S4–S11

By Dr Rakesh